HMG-CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

C.J.M. Doggen (Corresponding Author), R.N. Lemaitre, N.L. Smith, S.R. Heckbert, B.M. Psaty

Research output: Contribution to journalArticleAcademicpeer-review

81 Citations (Scopus)
11 Downloads (Pure)

Abstract

In addition to lowering blood lipid levels, statins (HMG CoA reductase inhibitors) inhibit platelet aggregation and maintain a favorable balance between prothrombotic and fibrinolytic mechanisms [1]. Perhaps these effects may account for the association of statins with a reduced risk of venous thrombosis [2,3]. Because different statins have different properties [4], the possibility that the risk of venous thrombosis varied by specific statin was also investigated.
Original languageEnglish
Pages (from-to)700-701
JournalJournal of thrombosis and haemostasis
Volume2
Issue number5
DOIs
Publication statusPublished - 2004
Externally publishedYes

Fingerprint Dive into the research topics of 'HMG-CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women'. Together they form a unique fingerprint.

Cite this